Market niche Target mid-sized pharmaceutical manufacturers focused on high-technological barrier solid oral specialty products, leveraging i3 Pharmaceuticals’ proven capabilities in difficult formulations to position as a preferred CDMO partner.

Financial leverage With reported revenue between 100M and 250M and recent funding of 16M, pursue partnerships or contract development arrangements that scale with modest risk, highlighting capacity for investment in advanced formulation and manufacturing capabilities.

Quality differentiation Stress core values of market insight, product ingenuity and uncompromising quality to attract customers seeking reliable, high-performance solid oral dosage forms with complex formulation requirements.

Tech-enabled delivery Highlight existing tech stack and digital capabilities to streamline collaboration, project management and regulatory documentation for clients needing efficient development timelines and transparent quality control.

Strategic partnerships Position as a nimble partner for larger players seeking specialized manufacturing capacity; propose co-development, technology transfer and strategic alliances to expand geographic reach and portfolio breadth.